

- 54 Long LP, Bai YP, Liu YS *et al.* Observation on the effect of glycyrrhizin complex on subacute and chronic eczema. *China Pharmacy* 2003; **14**: 37–38.
- 55 Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of atopic dermatitis with licorice gel. *J Dermatolog Treat* 2003; **14**: 153–157.
- 56 Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. *J Drugs Dermatol* 2006; **5**: 236–244.
- 57 Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063DP (Atopiclair) in the treatment of mild to moderate atopic dermatitis. *Eur J Dermatol* 2005; **15**: 31–36.
- 58 Kawashima S, Hayashi M, Takii T *et al.* Serotonin derivative N-(p-coumaroyl)-serotonin inhibits the production of TNF- α , IL-1 α , IL-1 β and IL-6 by endotoxin-stimulated human blood monocytes. *J Interferon Cyt Res* 1998; **18**: 423–428.
- 59 Xu Q, Yuan K, Lu J. A new strategy for regulating the immunological liver injury-effectiveness of DTH-inhibiting agents on DTH-induced liver injury to picryl chloride. *Pharmacol Res* 1997; **36**: 401–409.
- 60 Jiang J, Wu F, Lu J, Lu Z, Xu Q. Anti-inflammatory activity of the aqueous extract from *Rhizoma smilacis glabrae*. *Pharmacol Res* 1997; **36**: 309–314.
- 61 Jiang J, Xu Q. Immunomodulatory activity of the aqueous extract from rhizome of *smilax glabra* in the later phase of adjuvant-induced arthritis in rats. *J Ethnopharmacol* 2003; **85**: 53–59.
- 62 Fei M, Wu X, Xu Q. Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct cyclosporin A. *J Allergy Clin Immunol* 2005; **116**: 1350–1356.
- 63 Cai Y, Chen T, Xu Q. Astilbin suppresses delayed-type hypersensitivity by inhibiting lymphocyte migration. *J Pharm Pharmacol* 2003; **55**: 691–696.
- 64 Cai Y, Chen T, Xu Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. *Inflamm Res* 2003; **52**: 334–340.
- 65 Tu CX, Zhang XJ, Zhang YY *et al.* Clinical and experimental study on treatment of atopic dermatitis with glycyrrhizin. *Chin J Leprosy Skin Dis* 2007; **23**: 393–395 (in Chinese).
- 66 Demerjian M, Man MQ, Choi EH *et al.* Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. *Exp Dermatol* 2006; **15**: 154–160.

Supplementary material

The following supplementary material is available for this article online:

Figure S1. Topical application of Tuhuai extract does not effect epidermal proliferation significantly in normal skin: Either Vehicle or 1% Tuhuai extract was applied topically to normal intact skin twice daily for 4 days. Skin samples were taken 12 h after last treatment. a and c are H&E staining, and b and d are anti-PCNA staining. a and b are Vehicle-treated skin. c and d are Tuhuai-treated skin. The magnifications for all are the same. Scale bar = 20 μ m.

Figure S2. Topical application of Tuhuai extract reduces the inflammatory cell infiltration in both TPA and oxazolone models: Ear inflammation was induced by topical TPA or oxazolone treatment. Skin samples were obtained 20 h after treatment. Significant reductions in inflammatory cell infiltration and ear thickness were seen in Tuhuai-treated ear. a is normal ear. b (oxazolone) and c (TPA) are inflammatory ear treated with Vehicle. d (oxazolone) and e (TPA) are inflammatory ear treated with Tuhuai. Scale bar = 100 μ m.

This material is available as part of the online article from <http://www.blackwell-synergy.com>.

Please note: Blackwell publishing are not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.